4.14
price up icon2.48%   0.10
after-market アフターアワーズ: 4.32 0.18 +4.35%
loading
前日終値:
$4.04
開ける:
$4.05
24時間の取引高:
60,733
Relative Volume:
1.04
時価総額:
$35.79M
収益:
-
当期純損益:
$-42.19M
株価収益率:
-6.5714
EPS:
-0.63
ネットキャッシュフロー:
$-25.32M
1週間 パフォーマンス:
+43.25%
1か月 パフォーマンス:
+58.01%
6か月 パフォーマンス:
+2.73%
1年 パフォーマンス:
-58.19%
1日の値動き範囲:
Value
$3.7317
$4.3204
1週間の範囲:
Value
$2.836
$4.37
52週間の値動き範囲:
Value
$2.16
$69.99

Sab Biotherapeutics Inc Stock (SABS) Company Profile

Name
名前
Sab Biotherapeutics Inc
Name
セクター
Healthcare (1182)
Name
電話
305-845-2813
Name
住所
777 W 41ST ST, MIAMI BEACH
Name
職員
57
Name
Twitter
Name
次回の収益日
2024-11-12
Name
最新のSEC提出書
Name
SABS's Discussions on Twitter

Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2021-11-05 開始されました Chardan Capital Markets Buy

Sab Biotherapeutics Inc (SABS) 最新ニュース

pulisher
Oct 31, 2024

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire

Oct 31, 2024
pulisher
Oct 21, 2024

Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World

Oct 21, 2024
pulisher
Oct 17, 2024

SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register

Oct 17, 2024
pulisher
Oct 14, 2024

Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 14, 2024
pulisher
Sep 28, 2024

Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 12.7% - Defense World

Sep 28, 2024
pulisher
Sep 24, 2024

Saba Capital Income & Opportunities Fund II (NYSE:SABA) Major Shareholder Sells $37,672.38 in Stock - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Metric Analysis: Cassava Sciences Inc (SAVA)’s Key Ratios in the Limelight - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Healthy Upside Potential: Sabre Corp (SABR) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Assembly Biosciences keeps Neutral rating after Phase 1a study results - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

DSMB endorses continuation of Alzheimer's drug trials - Investing.com India

Sep 24, 2024
pulisher
Sep 23, 2024

Cassava Sciences Unusual Options Activity For September 23 - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance

Sep 23, 2024
pulisher
Sep 22, 2024

Renaissance Technologies LLC Lowers Stock Position in SBA Communications Co. (NASDAQ:SBAC) - Defense World

Sep 22, 2024
pulisher
Sep 22, 2024

Sabre Corporation (SABR): Among the Worst AI Stocks To Buy Under $10 - Yahoo Finance

Sep 22, 2024
pulisher
Sep 20, 2024

Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Morningstar

Sep 20, 2024
pulisher
Sep 14, 2024

SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World

Sep 13, 2024
pulisher
Sep 13, 2024

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire

Sep 13, 2024
pulisher
Sep 10, 2024

SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World

Sep 10, 2024
pulisher
Sep 09, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire

Sep 09, 2024
pulisher
Sep 09, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian

Sep 09, 2024
pulisher
Sep 09, 2024

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan

Sep 09, 2024
pulisher
Sep 04, 2024

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire

Sep 04, 2024
pulisher
Aug 28, 2024

SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World

Aug 28, 2024
pulisher
Aug 27, 2024

How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union

Aug 27, 2024
pulisher
Aug 26, 2024

Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart

Aug 26, 2024
pulisher
Aug 26, 2024

Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR

Aug 26, 2024
pulisher
Aug 15, 2024

Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World

Aug 15, 2024
pulisher
Aug 12, 2024

SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World

Aug 12, 2024
pulisher
Aug 12, 2024

SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World

Aug 12, 2024
pulisher
Aug 09, 2024

SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com

Aug 09, 2024
pulisher
Aug 08, 2024

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire

Aug 08, 2024
pulisher
Aug 08, 2024

Seasonal Influenza Treatment Market Size 2032 | SAb - openPR

Aug 08, 2024
pulisher
Aug 05, 2024

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire

Aug 05, 2024
pulisher
Jul 31, 2024

SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz

Jul 31, 2024
pulisher
Jul 21, 2024

SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News

Jul 21, 2024
pulisher
Jul 01, 2024

MarketBeat June market recap - SiouxFalls.Business

Jul 01, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow

Jun 30, 2024
pulisher
Jun 30, 2024

SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow

Jun 30, 2024
pulisher
Jun 28, 2024

Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World

Jun 28, 2024
pulisher
Jun 27, 2024

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Jun 27, 2024
pulisher
Jun 27, 2024

Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com

Jun 27, 2024
pulisher
Jun 27, 2024

CSP Inc insider buys shares worth over $23,000 - Investing.com

Jun 27, 2024
pulisher
Jun 27, 2024

Kintara Therapeutics restructures share designations By Investing.com - Investing.com

Jun 27, 2024
pulisher
Jun 26, 2024

Broker Revenue Forecasts For SAB Biotherapeutics, Inc. (NASDAQ:SABS) Are Surging Higher - Yahoo New Zealand News

Jun 26, 2024
pulisher
Jun 26, 2024

Need To Know: The Consensus Just Cut Its SAB Biotherapeutics, Inc. (NASDAQ:SABS) Estimates For 2022 - Yahoo Sport Australia

Jun 26, 2024
pulisher
Jun 20, 2024

SAB Bio updates brand to reflect focus on type 1 diabetes therapy By Investing.com - Investing.com Australia

Jun 20, 2024
pulisher
Jun 20, 2024

SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook (NASDAQ:SABS) - Seeking Alpha

Jun 20, 2024

Sab Biotherapeutics Inc (SABS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Sab Biotherapeutics Inc (SABS) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
King Michael
CHIEF FINANCIAL OFFICER
Nov 30 '23
Buy
0.90
5,000
4,500
5,000
Reich Samuel J
Executive Chairman
Nov 29 '23
Buy
0.89
11,000
9,842
219,001
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):